Heart Genomics pp 333-336 | Cite as

Warfarin and Its Pharmacogenomic Study

  • Shuiping Dai
Part of the Translational Bioinformatics book series (TRBIO, volume 16)


Warfarin as an anticoagulant is clinically prescribed to prevent blood clot formation. Genetic variants affect Warfarin response through pharmacokinetic and pharmacodynamic effects, which could account partially for the interracial difference to Warfarin. Warfarin activity is determined partially by the polymorphism in two genes, VKOPC1 and CYP2C9. Although the clinical application of pharmacogenomic information is controversial, the future gene sequencing and functional characterization of common genetic variation based on individual’s genetic information would provide a useful tool for precision medication.


Warfarin Anticoagulant Pharmacogenomics 



The author would like to thank Dr. Xiaobo Wu and Dr. Ming Liu for constructive criticism and helps.


  1. Jensen TS, Jacques LB, Ciccanti M, Long K, Eggleston L, Roche J. Decision memo for pharmacogenomic testing for warfarin response (CAG-00400N). Centers for Medicare and Medicaid Services. 2009.Google Scholar
  2. Kresge N, Simoni RD, Hill RL. Hemorrhagic sweet clover disease, Dicumarol and warfarin: the work of Karl Paul Link. J Biol Chem. 2005;280:e5.CrossRefGoogle Scholar
  3. Link KP. The discovery of Dicumarol and its sequels. Circulation. 1959;19:97–107.CrossRefGoogle Scholar
  4. Liu J, Jiang HH, Wu DK, Zhou YX, Ye HM, Li X, Luo ZY, Guo Z, Zhang YL, Wang YC, Zhang W, Zhou HH, Wang LS. Effect of gene polymorphims on the warfarin treatment at initial stage. Pharmacogenomics. 2017;17(1):47–52.CrossRefGoogle Scholar
  5. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005;352(22):2285–93.CrossRefGoogle Scholar
  6. Stergiopoulos K, Brown DL. Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials. JAMA Intern Med. 2014;174(8):1330–8.CrossRefGoogle Scholar
  7. Veenstra DL, You JH, Rieder MJ, Farin FM, Wilkerson HW, Blough DK, Cheng G, Rettie AE. Association of vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet Genomics. 2005;15(10):687–91.CrossRefGoogle Scholar
  8. Zhou HH, Adedoyin A, Wilkinson GR. Differences in plasma binding of drugs between Caucasians and Chinese subjects. Clin Pharmacol Ther. 1990;48(1):10–7.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  • Shuiping Dai
    • 1
  1. 1.University of Wisconsin Hospital and ClinicsMadisonUSA

Personalised recommendations